A series of novel compounds, generated through the hybridization of the cholinesterase inhibitor rivastigmine with several antioxidant aromatic moieties, was developed and evaluated for multiple biological activities with potential relevance to AD therapy. Here, BCHE is linked to Alzheimer disease.